Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Mudge, David W ^a   Johnson, David W ^a   Hawley, Carmel M ^a   Campbell, Scott B ^a   Isbel, Nicole M ^a   Van Eps, Carolyn L ^a   Petrie, James J B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; DIALYSIS FLUID; LANTHANUM; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; CHELATING AGENT; POLYAMINE;

ALUMINUM BLOOD LEVEL; ARTICLE; COST BENEFIT ANALYSIS; DIALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; NEPHROLOGY; NEUROTOXICITY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; BONE DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; HYPERPHOSPHATEMIA; KIDNEY DISEASE; RENAL REPLACEMENT THERAPY;

ALUMINUM; BONE DISEASES; CHELATING AGENTS; CHRONIC DISEASE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; LANTHANUM; POLYAMINES; RENAL DIALYSIS;

EID: 79958120434     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-20     Document Type: Article

References (31)

1. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. E Slatopolsky S Caglar JP Pennell DD Taggart JM Canterbury E Reiss,, et al. J Clin Invest 1971 50 492 499 10.1172/JCI106517 5545116
2. An evaluation of a new and effective phosphorus binding agent. E Rutherford A Mercado K Hruska H Harter N Mason R Sparks,, et al. Trans Am Soc Artif Intern Organs 1973 19 446 449 4722760
3. The dialysis encephalopathy syndrome. Possible aluminum intoxication. AC Alfrey GR LeGendre WD Kaehny, N Engl J Med 1976 294 184 188 10.1056/ NEJM197601222940402 1244532
4. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. JM Candy FK McArthur AE Oakley GA Taylor CP Chen SA Mountfort,, et al. J Neurol Sci 1992 107 210 218 10.1016/0022-510X(92)90291-R 1564520
5. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era]. MD Arenas T Malek MT Gil A Moledous C Nunez F Alvarez-Ude, Nefrologia 2008 28 168 173 18454706
6. Aluminum removal by hemodialysis. H Graf HK Stummvoll V Meisinger J Kovarik A Wolf WF Pinggera, Kidney Int 1981 19 587 592 10.1038/ki.1981.56 7241891 (Pubitemid 11120905)
7. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. IS Parkinson MK Ward TG Feest RW Fawcett DN Kerr, Lancet 1979 1 406 409 84261 (Pubitemid 9121127)
8. Letter: Aluminum and dialysis dementia. JA Flendrig H Kruis HA Das, Lancet 1976 1 1235 58274
9. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. AI Short RJ Winney JS Robson, Proc Eur Dial Transplant Assoc 1980 17 226 233 7243773
10. Aluminium-related osteomalacia: response to reverse osmosis water treatment. GD Smith RJ Winney A McLean JS Robson, Kidney Int 1987 32 96 101 10.1038/ki.1987.177 3626303 (Pubitemid 17094504)
11. Relative roles of intestinal absorption and dialysis-fluid-related exposure in the accumulation of aluminium in haemodialysis patients. S Mazzaferro I Perruzza S Costantini M Pasquali L Onorato D Sardella,, et al. Nephrol Dial Transplant 1997 12 2679 2682 10.1093/ndt/12.12.2679 9430871 (Pubitemid 27520694)
12. Encephalopathy in infants and children with chronic renal disease. CM Foley MS Polinsky AB Gruskin HJ Baluarte WD Grover, Arch Neurol 1981 38 656 658 7295112 (Pubitemid 11019181)
13. Aluminium absorption and antacid therapy in infancy. L Woodard-Knight A Fudge J Teubner K Simmer, J Paediatr Child Health 1992 28 257 259 10.1111/j.1440-1754.1992.tb02658.x 1605980
14. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. SP Andreoli JM Bergstein DJ Sherrard, N Engl J Med 1984 310 1079 1084 10.1056/NEJM198404263101704 6708989 (Pubitemid 14131500)
15. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. AA Bakir DO Hryhorczuk E Berman G Dunea, ASAIO Trans 1986 32 171 176 3778707
16. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. BB Kirschbaum AC Schoolwerth, Am J Med Sci 1989 297 9 11 10.1097/00000441-198901000-00003 2913801 (Pubitemid 19063866)
17. Effect of solubility on the gastrointestinal absorption of aluminum from various aluminum compounds in the rat. DH Froment B Buddington NL Miller AC Alfrey, J Lab Clin Med 1989 114 237 242 2769017 (Pubitemid 19221255)
18. Citrate: a major factor in the toxicity of orally administered aluminum compounds. BA Molitoris DH Froment TA Mackenzie WH Huffer AC Alfrey, Kidney Int 1989 36 949 953 10.1038/ki.1989.286 2689754 (Pubitemid 20049198)
19. Frequency of elevated serum aluminum levels in adult dialysis patients. JA Jaffe C Liftman JD Glickman, Am J Kidney Dis 2005 46 316 319 10.1053/j.ajkd.2005.04.020 16112051 (Pubitemid 41040361)
20. Plasma aluminium: a redundant test for patients on dialysis? PM Gault KR Allen KE Newton, Ann Clin Biochem 2005 42 51 54 10.1258/0004563053026862 15802033 (Pubitemid 40209066)
21. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. AT Kausz JE Antonsen G Hercz Y Pei NS Weiss S Emerson,, et al. Am J Kidney Dis 1999 34 688 693 10.1016/S0272-6386(99) 70394-X 10516350 (Pubitemid 29473056)
22. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. CL van Eps JK Jeffries JA Anderson PT Bergin DW Johnson SB Campbell,, et al. Nephrology (Carlton) 2007 12 224 233 10.1111/j.1440-1797.2006.00712.x (Pubitemid 46718196)
23. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. GA Block PS Klassen JM Lazarus N Ofsthun EG Lowrie GM Chertow, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
24. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 1 201 14520607
25. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. SC Cheng DO Young Y Huang JA Delmez DW Coyne, Clin J Am Soc Nephrol 2008 3 1131 1138 10.2215/CJN.04211007 18385391
26. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the USA. B Manns L Stevens D Miskulin WF Owen Jr WC Winkelmayer M Tonelli, Kidney Int 2004 66 1239 1247 10.1111/j.1523-1755.2004. 00877.x 15327423 (Pubitemid 39121034)
27. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. WN Suki R Zabaneh JL Cangiano J Reed D Fischer L Garrett,, et al. Kidney Int 2007 72 1130 1137 10.1038/sj.ki.5002466 17728707 (Pubitemid 47609037)
28. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. MJ Janssen KA van der PM ter Wee WP van Boven, Clin Nephrol 1996 45 111 119 8846523 (Pubitemid 26056959)
29. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. KP Katopodis EK Andrikos CD Gouva ET Bairaktari PM Nikolopoulos LK Takouli,, et al. Perit Dial Int 2006 26 320 327 16722024 (Pubitemid 44339999)
30. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. GB Spasovski A Sikole S Gelev J Masin-Spasovska T Freemont I Webster,, et al. Nephrol Dial Transplant 2006 21 2217 2224 10.1093/ndt/gfl146 16595583 (Pubitemid 44295048)
31. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. B Lacour A Lucas D Auchere N Ruellan NM Serre Patey TB Drueke, Kidney Int 2005 67 1062 1069 10.1111/j.1523-1755. 2005.00171.x 15698446 (Pubitemid 41623331)